Grant W. Margulieux
Associate
Grant Margulieux assists clients in the pharmaceutical, materials, and biotech industries on a wide range of intellectual property issues, including strategic patent portfolio development, patentability, non-infringement, and freedom to operate. Grant has over a decade of experience representing clients, particularly those pursuing small molecule therapeutics.
Prior to joining the firm, Grant completed his doctoral degree in synthetic chemistry at Princeton University. His dissertation focused on the development and synthesis of catalysts and their uses in the production of pharmaceuticals, fine chemicals, synthetic materials, and alternative fuels. Grant also possesses a strong background in X-ray crystallography.
Experience
Grant Margulieux assists clients in the pharmaceutical, materials, and biotech industries on a wide range of intellectual property issues, including strategic patent portfolio development, patentability, non-infringement, and freedom to operate. Grant has over a decade of experience representing clients, particularly those pursuing small molecule therapeutics.
Prior to joining the firm, Grant completed his doctoral degree in synthetic chemistry at Princeton University. His dissertation focused on the development and synthesis of catalysts and their uses in the production of pharmaceuticals, fine chemicals, synthetic materials, and alternative fuels. Grant also possesses a strong background in X-ray crystallography.
Education
- J.D., University of San Diego School of Law
- Ph.D., Chemistry, Princeton University, 2015
- M.S., Chemistry, University of California, San Diego, 2011
- B.S., Molecular Synthesis, University of California, San Diego, 2009
Admissions
- State Bar of California
- U.S. Patent and Trademark Office
Credentials
Education
- J.D., University of San Diego School of Law
- Ph.D., Chemistry, Princeton University, 2015
- M.S., Chemistry, University of California, San Diego, 2011
- B.S., Molecular Synthesis, University of California, San Diego, 2009
Admissions
- State Bar of California
- U.S. Patent and Trademark Office
Select Publications
- Co-author with M.F. Friedfeld, M. Shelvin, L.C. Campeau, and P.J. Chirik, "Cobalt-Catalyzed Enantioselective Hydrogenation of Minimally Functionalized Alkenes: Isotopic Labeling Provides Insight into the Origin of Stereoselectivity," 138(10) Journal of the American Chemical Society 3314-24, 2016
- Co-author with B.A. Schaefer, B.L. Small, and P.J. Chirik, "Evaluation of Cobalt Complexes Bearing Tridentate Pincer Ligands for Catalytic C-H Borylation," 34(7) Organometallics 1307-20, 2015
- Co-author with C.C. Mokhtarzadeh, A.E. Carpenter, N. Weidemann, C.E. Moore, A.L. Rheingold, and J.S. Figueroa, "Synthesis and Protonation of an Encumbered Iron Tetraisocyanide Dianion," 54(11) Inorganic Chemistry 5579-87, 2015
- Co-author with Z.R. Turner and P.J. Chirik, "Synthesis and Ligand Modification Chemistry of a Molybdenum Dinitrogen Complex: Redox and Chemical Activity of a Bis-(imino)pyridine Ligand," 53(51) Angewandte Chemie International Edition 14211-5, 2014
- Co-author with M.R. Friedfeld, B.A. Schaefer, and P.J. Chirik, "Bis(phosphine)cobalt Dialkyl Complexes for Directed Catalytic Alkene Hydrogenation," 136(38) Journal of the American Chemical Society 13178-81, 2014
- Co-author with S.P. Semproni and P.J. Chirik, "Photochemically Induced Reductive Elimination as a Route to a Zirconocene Complex with a Strongly Activated N2 Ligand," 53(35) Angewandte Chemie International Edition 9189-92, 2014
- Co-author with J.M. Hoyt, M. Shelvin, S.W. Krska, M.T. Tudge, and P.J. Chirik, "Synthesis and Hydrogenation Activity of Iron Dialkyl Complexes with Chiral Bidentate Phosphines," 33(20) Organometallics 5781-90, 2014
- Co-author with R. Yu, J.M. Darmon, C. Milsmann, S.E. Stieber, S. DeBeer, and P.J. Chirik, "Catalytic Hydrogenation Activity and Electronic Structure Determination of Bis(arylimidazol-2-ylidene)pyridine Cobalt Alkyl and Hydride Complexes," 135(35) Journal of the American Chemical Society 13168-84, 2013
- Co-author S.P. Semproni and P.J. Chirik, "Di- and Tetrametallic Hafnocene Oxamidides Prepared from CO-Induced N2 Bond Cleavage and Thermal Rearrangement to Hafnocene Cyanide Derivatives," 31(17) Organometallics 6278-87, 2012
- Co-author with R. Yu, J.D. Darmon, J.M. Hoyt, Z.R. Turner, and P.J. Chirik, "High-Activity Iron Catalysts for Hydrogenation of Hindered, Unfunctionalized Alkenes," 2(8) ACS Catalysis 1760-4, 2012
- Co-author with A.E. Carpenter, M.D. Millard, C.E. Moore, N. Weidemann, A.L. Rheingold, and J.S. Figueroa, "Zwitterionic Stabilization of a Reactive Cobalt Tri-Isocyanide Monoanion by Cation Coordination,"51(37) Angewandte Chemie International Edition 9412-6, 2012
- Co-author with N. Weidemann, C.E. Moore, A.L. Rheingold, and J.S. Figueroa, "Structural Variation in Cobalt Halide Complexes Supported by m-Terphenyl Isocyanides," 364(1) Inorganica Chimica Acta 238-45, 2010
- Co-author with N. Weidemann, D.C. Lacy, C.E. Moore, A.L. Rheingold, and J.S. Figueroa, "Isocyano Analogues of [Co(CO)4]n: A Tetraisocyanide of Cobalt Isolated in Three States of Charge," 132(14) Journal of the American Chemical Society 5033-5, 2010
Insights
Select Publications
- Co-author with M.F. Friedfeld, M. Shelvin, L.C. Campeau, and P.J. Chirik, "Cobalt-Catalyzed Enantioselective Hydrogenation of Minimally Functionalized Alkenes: Isotopic Labeling Provides Insight into the Origin of Stereoselectivity," 138(10) Journal of the American Chemical Society 3314-24, 2016
- Co-author with B.A. Schaefer, B.L. Small, and P.J. Chirik, "Evaluation of Cobalt Complexes Bearing Tridentate Pincer Ligands for Catalytic C-H Borylation," 34(7) Organometallics 1307-20, 2015
- Co-author with C.C. Mokhtarzadeh, A.E. Carpenter, N. Weidemann, C.E. Moore, A.L. Rheingold, and J.S. Figueroa, "Synthesis and Protonation of an Encumbered Iron Tetraisocyanide Dianion," 54(11) Inorganic Chemistry 5579-87, 2015
- Co-author with Z.R. Turner and P.J. Chirik, "Synthesis and Ligand Modification Chemistry of a Molybdenum Dinitrogen Complex: Redox and Chemical Activity of a Bis-(imino)pyridine Ligand," 53(51) Angewandte Chemie International Edition 14211-5, 2014
- Co-author with M.R. Friedfeld, B.A. Schaefer, and P.J. Chirik, "Bis(phosphine)cobalt Dialkyl Complexes for Directed Catalytic Alkene Hydrogenation," 136(38) Journal of the American Chemical Society 13178-81, 2014
- Co-author with S.P. Semproni and P.J. Chirik, "Photochemically Induced Reductive Elimination as a Route to a Zirconocene Complex with a Strongly Activated N2 Ligand," 53(35) Angewandte Chemie International Edition 9189-92, 2014
- Co-author with J.M. Hoyt, M. Shelvin, S.W. Krska, M.T. Tudge, and P.J. Chirik, "Synthesis and Hydrogenation Activity of Iron Dialkyl Complexes with Chiral Bidentate Phosphines," 33(20) Organometallics 5781-90, 2014
- Co-author with R. Yu, J.M. Darmon, C. Milsmann, S.E. Stieber, S. DeBeer, and P.J. Chirik, "Catalytic Hydrogenation Activity and Electronic Structure Determination of Bis(arylimidazol-2-ylidene)pyridine Cobalt Alkyl and Hydride Complexes," 135(35) Journal of the American Chemical Society 13168-84, 2013
- Co-author S.P. Semproni and P.J. Chirik, "Di- and Tetrametallic Hafnocene Oxamidides Prepared from CO-Induced N2 Bond Cleavage and Thermal Rearrangement to Hafnocene Cyanide Derivatives," 31(17) Organometallics 6278-87, 2012
- Co-author with R. Yu, J.D. Darmon, J.M. Hoyt, Z.R. Turner, and P.J. Chirik, "High-Activity Iron Catalysts for Hydrogenation of Hindered, Unfunctionalized Alkenes," 2(8) ACS Catalysis 1760-4, 2012
- Co-author with A.E. Carpenter, M.D. Millard, C.E. Moore, N. Weidemann, A.L. Rheingold, and J.S. Figueroa, "Zwitterionic Stabilization of a Reactive Cobalt Tri-Isocyanide Monoanion by Cation Coordination,"51(37) Angewandte Chemie International Edition 9412-6, 2012
- Co-author with N. Weidemann, C.E. Moore, A.L. Rheingold, and J.S. Figueroa, "Structural Variation in Cobalt Halide Complexes Supported by m-Terphenyl Isocyanides," 364(1) Inorganica Chimica Acta 238-45, 2010
- Co-author with N. Weidemann, D.C. Lacy, C.E. Moore, A.L. Rheingold, and J.S. Figueroa, "Isocyano Analogues of [Co(CO)4]n: A Tetraisocyanide of Cobalt Isolated in Three States of Charge," 132(14) Journal of the American Chemical Society 5033-5, 2010
Therapeutics and Drug Discovery
- Drug conjugates
- Drug conjugates based drug discovery
- Drug delivery
- Pharmacokinetics
- Pharmacology
- Small molecule synthesis
- Small molecules
Chemistry and Material Science
- Catalysis
- Chemical synthesis
- Chemistry
- Green chemistry
- Materials chemistry
- Organic chemistry
- Organometallics
- Polymers
- Polymorph
Engineering and Technology
- Materials science
Miscellaneous
- Food science
- Formulations
- Plant patents
Technical Fluency
Therapeutics and Drug Discovery
- Drug conjugates
- Drug conjugates based drug discovery
- Drug delivery
- Pharmacokinetics
- Pharmacology
- Small molecule synthesis
- Small molecules
Chemistry and Material Science
- Catalysis
- Chemical synthesis
- Chemistry
- Green chemistry
- Materials chemistry
- Organic chemistry
- Organometallics
- Polymers
- Polymorph
Engineering and Technology
- Materials science
Miscellaneous
- Food science
- Formulations
- Plant patents
Recent Insights
Client Highlights
Firm Advises Ona Therapeutics on IP Matters Related to $86.6 Million Series B
On June 4, 2026, Ona Therapeutics, a global biopharmaceutical company pioneering first-in-class antibody-drug conjugates (ADCs) to address treatment-resistant cancers, announced the closing of an oversubscribed $86.6 million Series B financing. The round was co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Alta Life Sciences, Asabys Partners, Bpifrance, as part of the InnoBio investment strategy, CDTI through SICC Innvierte, FundPlus NV, and Ysios Capital. Wilson Sonsini Goodrich & Rosati advised Ona Therapeutics on IP matters related to the transaction.
The proceeds from the Series B will be used to advance the clinical development of Ona’s lead program, ONA-255, a first-in-class ADC initially focused on breast cancer, and to progress ONA-389, a second first-in-class ADC targeting colorectal cancer. ONA-255 is designed to address treatment-resistant tumor biology through a differentiated mechanism aimed at improving the therapeutic index compared to earlier approaches. ONA-389 will advance toward first-in-human studies, expanding Ona’s pipeline in indications with significant unmet need. Ona currently retains full worldwide commercial rights to all its assets.
The proceeds from the Series B will be used to advance the clinical development of Ona’s lead program, ONA-255, a first-in-class ADC initially focused on breast cancer, and to progress ONA-389, a second first-in-class ADC targeting colorectal cancer. ONA-255 is designed to address treatment-resistant tumor biology through a differentiated mechanism aimed at improving the therapeutic index compared to earlier approaches. ONA-389 will advance toward first-in-human studies, expanding Ona’s pipeline in indications with significant unmet need. Ona currently retains full worldwide commercial rights to all its assets.
Learn More
Client Highlights
Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion
On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.